LUNA INNOVATIONS INCORPORATED — Department of Defense SBIR Phase I: CBD181-005

Description

In response to the defined need for minimizing the carry weight of combat teams while retaining capability, Luna Innovations is proposing the development of a stable formulation of atropine and scopolamine for use in an autoinjector to combat nerve agent intoxication. The combined formulation of atropine and scopolamine will allow for better treatment with more physiological coverage within the human body, will reduce the number of total autoinjectors combat teams need to carry, and will enable greater overall agility and responsiveness of military personnel. Luna will be rapidly demonstrating a stable combined formulation of atropine and scopolamine compatible with intramuscular injection using proven molecular stabilization technologies. These stabilization technologies have been previously demonstrated by Luna to be adept at conserving small molecules and biologicals at room temperature or elevated temperature. Both atropine and scopolamine will be stabilized and stored under ICH-recommended conditions and stability evaluated at intervals using a mock intramuscular injection. Further, the regulation strategy of this technology will be forecast, as well as preliminary evaluation of commercialization prospects of Luna's pharmaceutical stabilization technology.